A carregar...
Learning from the Recently Completed Oral Glycoprotein IIb/IIIa Receptor Antagonist Trials
Although parenteral therapy with glycoprotein (GP) IIb/IIIa inhibitors has resulted in a reduced risk of death or myocardial infarction in patients with acute coronary syndromes and in patients undergoing percutaneous coronary intervention, the benefit is achieved only during the infusion period. Or...
Na minha lista:
| Publicado no: | Clin Cardiol |
|---|---|
| Autor principal: | |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Wiley Periodicals, Inc.
2009
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6654967/ https://ncbi.nlm.nih.gov/pubmed/11129681 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/clc.4960231105 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|